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Dosing antibiotics in critically ill patients to achieve
therapeutic concentrations is a significant challenge.
The presence of septic shock and prescription of
continuous renal replacement therapy introduces
further complexities for the clinician. Unfortunately,
this is a dilemma encountered daily by intensivists.
Although small pharmacokinetic studies are emerging
to provide data to help address this problem, the
variability in results from these studies is profound. As
such, effective antibiotic dosing guidelines for critically
ill patients who have septic shock and who receive
continuous renal replacement therapy are not
available. Dosing flowcharts and therapeutic drug
monitoring represent the best available options for
clinicians to optimize antibiotic dosing.tions associated with maximal bacterial killing is essen-The review article from Ulldemolins and colleagues [1] in
this issue of Critical Care seeks to describe the challenges
of beta-lactam antibiotic dosing in critically ill patients
who have septic shock and who are receiving continuous
renal replacement therapy (CRRT). Along with patients on
extracorporeal membrane oxygenation [2] or those with
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2014function [4], the patient population reviewed here is one of
the most challenging for drug dosing [5,6].
The dosing of antibiotics is more complex than that of
other therapeutic classes, such as sedatives, vasoactive
agents, and other drugs commonly used in the intensive
care unit, because an ‘end-of-needle’ effect is not appar-
ent. This complicates attempts to titrate antibiotic dos-
ing on the basis of clinical evolution. Given that
critically ill patients who have sepsis and who are receiv-
ing renal replacement therapy (RRT) have a 50% higher
mortality than their non-septic equivalents and that the
mortality rate is unacceptably high (more than 60%) [7],
optimizing antibiotic therapy should be seen as vital to
improve patient outcomes. However, optimal dosing in
such patients is clearly a challenge [5,6], and effective
guidance on empiric dosing in at-risk individuals is
needed. Ensuring that empiric doses achieve concentra-
tial to therapeutic success.
The review by Ulldemolins and colleagues [1] describes
the challenges of antibiotic prescribing to critically ill pa-
tients who have septic shock and who are receiving CRRT.
The authors have tackled a complex question and in doing
so have considered both mechanistic concepts and clinical
data, for which they should be complimented. They have
presented their findings clearly and integrated various
pharmacokinetic and pharmacodynamic principles in the
process of developing their recommendations.
The authors highlight some interesting concepts based
on pharmacokinetic differences between three selected
antibiotics: ceftriaxone, piperacillin, and meropenem.
Ceftriaxone has high, but variable, protein binding [8],Central Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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protein-bound drugs is higher during CRRT in critically
ill patients compared with intermittent hemodialysis,
most likely due to the common presence of hypoalbumin-
emia [9]. For antibiotics that have multiple elimination
pathways (renal and biliary for ceftriaxone and piperacillin),
the presence of acute kidney injury appears to cause a rela-
tive upregulation of non-renal pathways. This causes the
antibiotic concentration to be lower than that predicted by
the proportional change in renal function, as demonstrated
with piperacillin [10]. Therefore, knowledge of the pharma-
cokinetic characteristics of an antibiotic may help predict
changes in antibiotic concentration in different clinical sce-
narios. Unfortunately, the generalizability of these con-
cepts, clinical relevance, and individual contribution to the
overall pharmacokinetic variability remain less certain be-
cause of limitations in the available data.
CRRT enhances the elimination of antibiotics, and so
this effect must be anticipated and the dosing regimen
adjusted. Important components that should be consid-
ered include the CRRT technical settings (in particular,
the rate of effluent production) and duration of use (on-
and off-time). The authors highlight that the delivered
dose of RRT is an informative predictor of antibiotic
clearance. Subsequent to the literature review by Ullde-
molins and colleagues, a published meta-review by Jamal
and colleagues [11] demonstrated that in critically ill pa-
tients receiving RRT the effluent flow rate correlates (al-
beit not statistically significantly) with extracorporeal
beta-lactam clearance in CRRT for meropenem (rs =
0.43; P = 0.12), piperacillin (rs = 0.77; P = 0.10), and
vancomycin (rs = 0.90; P = 0.08). Although antibiotic
clearance in these patients has not been well correlated
with achievement of therapeutic concentrations, one
would assume that a strong relationship does exist. Fur-
thermore, knowledge of recovering renal function is im-
portant given that this is a pathway for additional drug
excretion for many beta-lactams in these patients.
Given the sources of beta-lactam pharmacokinetic vari-
ability highlighted, Ulldemolins and colleagues suggest a
general approach to dosing of patients. Although the con-
cepts are useful, a paucity of data means that robust guid-
ance and conclusions are limited. For example, data on the
size of loading doses, the influence of patient morphology
(for example, obese versus non-obese), sites of infections
(for example, deep-seated infections), susceptibility of the
bacteria, and the risks from antibiotic overdosing (for ex-
ample, toxicity and cost) are not included. It is anticipated
that these factors are important considerations for optimiz-
ing beta-lactam dosing, although their significance on the
basis of existing data and the other complex changes noted
in critical illness requires further research. Other research
of interest, prompted by this research, includes the utility
of biomarkers of organ function and disease severity forguiding antibiotic dosing and the clinical impact of dose
optimization on patient outcomes. The poor overall out-
comes of critically ill patients with sepsis mandate the im-
portance of such research.
To develop a dosing guideline that accounts for variation
in each of these parameters as well as in RRT modalities
and settings, a large multicenter RRT pharmacokinetic
study is required. The newly commencing SMARRT (SaM-
pling Antibiotics in Renal Replacement Therapy) Study
may, in time, provide such answers (Australian New
Zealand Clinical Trials Registry ACTRN12613000241730).
Until such a robust guideline becomes available, clini-
cians will be reliant on applying dosing flowcharts such as
that proposed by Choi and colleagues [12] or by actually
measuring antibiotic concentrations using therapeutic drug
monitoring (TDM) [13,14]. Although various difficulties
are associated with establishing and running a TDM pro-
gram for beta-lactams in critically ill patients, it remains
the only way to know with certainty whether the patient
has therapeutic exposures of the prescribed beta-lactam
antibiotic and so must be considered a desirable interven-
tion for optimizing care of critically ill patients with septic
shock [5].
Abbreviations
CRRT: Continuous renal replacement therapy; RRT: Renal replacement
therapy; TDM: Therapeutic drug monitoring.
Competing interests
The authors declare that they have no competing interests.
Acknowledgments
JAR is funded in part by an Australian National Health and Medical Research
Council (NHMRC) Fellowship (APP1048652) and acknowledges the funding
provided by NHMRC Project grants APP1044941 and APP1062040.
Author details
1Burns Trauma and Critical Care Research Centre, School of Medicine, The
University of Queensland, Level 3 Ned Hanlon Building, Royal Brisbane and
Women’s Hospital, Butterfield Street, Herston, Queensland 4029, Australia.
2Royal Brisbane and Women’s Hospital, Butterfield Street, Herston,
Queensland 4029, Australia. 3Department of Molecular and Clinical
Pharmacology, The University of Liverpool, Ashton StreetLiverpool L69 3GE, UK.
Published:
References
1. Ulldemolins M, Vaquer S, Llaurado-Serra M, Pontes C, Calvo G, Soy D,
Martin-Loeches I: Beta lactam dosing in critically ill patient with septic
shock and continuous renal replacement therapy. Crit Care 2014, 18:227.
2. Shekar K, Roberts JA, Ghassabian S, Mullany DV, Wallis SC, Smith MT, Fraser
JF: Altered antibiotic pharmacokinetics during extracorporeal membrane
oxygenation: cause for concern? J Antimicrob Chemother 2013, 68:726–727.
3. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J: Augmented renal
clearance: implications for antibacterial dosing in the critically ill. Clin
Pharmacokinet 2010, 49:1–16.
4. Blot S, Lipman J, Roberts DM, Roberts JA: The influence of acute kidney
injury on antimicrobial dosing in critically ill patients: are dose
reductions always necessary? Diagn Microbiol Infect Dis 2014, 79:77–84.
5. Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, Jacobs F:
Recommended beta-lactam regimens are inadequate in septic patients
treated with continuous renal replacement therapy. Crit Care 2011, 15:R137.
23 Jun 2014
Roberts and Roberts Critical Care Page 3 of 32014, 18:156
http://ccforum.com/content/18/3/1566. Roberts DM, Roberts JA, Roberts MS, Liu X, Cole CL, Nair P, Lipman J,
Bellomo R: Variability of antibiotic concentrations in critically ill patients
receiving continuous renal replacement therapy – a multicentre
pharmacokinetic study. Crit Care Med 2012, 40:1523–1528.
7. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I,
Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM,
Ronco C, Kellum JA, Beginning and Ending Supportive Therapy for the
Kidney (BEST Kidney) Investigators: Septic acute kidney injury in critically
ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol
2007, 2:431–439.
8. Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA:
Protein binding of beta-lactam antibiotics in critically ill patients: can we
successfully predict unbound concentrations? Antimicrob Agents
Chemother 2013, 57:6165–6170.
9. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J: The effects of
hypoalbuminaemia on optimising antibiotic dosing in critically ill
patients. Clin Pharmacokinet 2011, 50:99–110.
10. Brogard JM, Jehl F, Blickle JF, Dorner M, Arnaud JP, Monteil H: Biliary
pharmacokinetic profile of piperacillin: experimental data and evaluation
in man. Int J Clin Pharmacol Ther Toxicol 1990, 28:462–470.
11. Jamal JA, Udy AA, Lipman J, Roberts JA: The impact of variation in renal
replacement therapy settings on piperacillin, meropenem, and
vancomycin drug clearance in the critically ill: an analysis of published
literature and dosing regimens. Crit Care Med 2014. Mar 26 [Epub ahead of
print].
12. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J: Principles
of antibacterial dosing in continuous renal replacement therapy.
Crit Care Med 2009, 37:2268–2282.
13. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA: Does beta-lactam
pharmacokinetic variability in critically ill patients justify therapeutic
drug monitoring? A systematic review. Ann Intensive Care 2012, 2:35.
14. Roberts JA, Hope WW, Lipman J: Therapeutic drug monitoring of
beta-lactams for critically ill patients: unwarranted or essential?
Int J Antimicrob Agents 2010, 35:419–420.
Cite this article as: Roberts and Roberts: Antibiotic dosing in critically ill
patients with septic shock and on continuous renal replacement
therapy: can we resolve this problem with pharmacokinetic studies and
dosing guidelines? Critical Care
10.1186/cc13939
2014, 18:156
